文献速递慢阻肺

茚达特罗/格隆溴铵对过度充气慢阻肺患者肺灌注与通气的影响:CLAIM双盲随机交叉试验

Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

MRI显示该双支气管舒张剂显著改善总肺微血管血流(P=0.006)及区域肺微血管血流(各肺叶P值0.004~0.022),并显著改善区域通气。

要点

  • 茚达特罗/格隆溴铵显著改善过度充气慢阻肺患者的总肺微血管血流(P=0.006)。
  • 区域通气较安慰剂增加12.4%(P=0.011),通气缺陷百分比相对降低14.3%(P=0.0002)。
  • 区域通气变异系数较安慰剂降低15.7%(P<0.0001)。

核心结论

  • 茚达特罗/格隆溴铵药物治疗可改善过度充气慢阻肺患者的肺微血管血流和区域通气。

研究设计与样本

  • 患者接受每日一次茚达特罗/格隆溴铵(110/50 μg)14天与安慰剂14天,两治疗期间隔14天洗脱。
  • 采用钆增强MRI测量肺微血管血流,采用相位分辨功能肺MRI测量区域通气。

主要发现

  • 与安慰剂相比,茚达特罗/格隆溴铵使总肺微血管血流显著改善(P=0.006)。
  • 各肺叶区域肺微血管血流显著改善,P值范围为0.004~0.022。
  • 区域通气较安慰剂增加12.4%(P=0.011)。
  • 未通气/低通气肺组织的通气缺陷百分比相对降低14.3%(阈值定义为区域通气0.075;P=0.0002)。
  • 区域通气变异系数较安慰剂降低15.7%(P<0.0001)。

临床怎么用

  • 对过度充气慢阻肺患者,茚达特罗/格隆溴铵在改善过度充气的同时可改善肺微血管血流和区域通气。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: In the CLAIM study, dual bronchodilation with indacaterol/glycopyrronium (IND/GLY) significantly reduced hyperinflation, which translated into improved cardiac function, measured by left ventricular end-diastolic volume and cardiac output. Pulmonary microvascular blood flow (PMBF) is reduced in chronic obstructive pulmonary disease (COPD); however, the effect of reduced lung hyperinflation on PMBF remains unknown. Objectives: To determine the effect of lung deflation with IND/GLY on PMBF and regional pulmonary ventilation using magnetic resonance imaging (MRI) in hyperinflated patients with COPD. Methods: In this double-blind, randomized, two-period crossover study, gadolinium-enhanced MRI and phase-resolved functional lung MRI were used to measure PMBF and regional ventilation, respectively, in patients with COPD receiving IND/GLY versus placebo. Measurements and Main Results: Sixty-two patients were randomized to receive once-daily IND/GLY (110/50 μg) for 14 days, followed by 14 days of placebo, or vice versa. Treatment periods were separated by a 14-day washout. Sixty patients were included in the per-protocol analysis. MRI measurements showed significant improvements in total PMBF (P = 0.006) and regional PMBF (P values for individual lobes were between 0.004 and 0.022) in response to IND/GLY versus placebo. Regional ventilation was also significantly improved with IND/GLY, as evidenced by a 12.4% increase versus placebo (P = 0.011), a 14.3% relative decrease in ventilation defect percentage of nonventilated/hypoventilated lung tissue (cutoff was defined as 0.075 regional ventilation; P = 0.0002), and a 15.7% reduction in the coefficient of variation of regional ventilation compared with placebo (P < 0.0001). Conclusions: Pharmacologic intervention with IND/GLY improves pulmonary microvascular blood flow and regional ventilation in patients with COPD with hyperinflation. Clinical trial registered with www.clinicaltrials.gov (NCT02442206).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Vogel-Claussen J, Schönfeld CO, Kaireit TF, et al. Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial. Am J Respir Crit Care Med. 2019. PMID: 30641027. doi:10.1164/rccm.201805-0995OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。